Form 4: Akero Therapeutics Executive Sells Shares Under 10b5-1 Trading Plan
SEC Form 4
Patrick Lamy, Senior VP of Commercial Strategy at Akero Therapeutics, sold shares of common stock and exercised stock options under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Patrick Lamy, Senior VP of Commercial Strategy at Akero Therapeutics, executed transactions involving the company's stock on May 7, 2025.
- These transactions included the exercise of stock options to acquire 8,000 shares at a price of $19.87 per share and the sale of 8,000 shares in the open market.
- The sales were conducted in multiple transactions at weighted-average prices of $42.309 and $42.757.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on January 6, 2025.
- Following these transactions, Lamy directly owns 33,492 shares of common stock and 70,182 stock options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The filing itself doesn't provide insight into the company's performance or future prospects, but it does indicate that a key executive is liquidating some of their holdings.
Key Dates
| Date | Description |
|---|---|
| 2023-12-08 | Commencement date for monthly vesting of stock options. |
| 2025-01-06 | Date of adoption of the Rule 10b5-1 trading plan. |
| 2025-05-07 | Date of the reported transactions (exercise of options and sale of shares). |
| 2025-05-09 | Date of signature on the Form 4 filing. |
| 2033-12-07 | Expiration date of the stock options. |
Keywords
Akero Therapeutics, AKRO, Patrick Lamy, Stock Options, Share Sales, Form 4, Rule 10b5-1, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.